Literature DB >> 263873

Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines.

R E Weibel, E B Buynak, A A McLean, M R Hilleman.   

Abstract

Hemagglutination-inhibiting antibodies were retained in comparable levels eight years after vaccination with Enders' original Edmonston and more attenuated Moraten (Attenuvax) and Schwarz line measles vaccines. Neutralizing antibody persisted without substantial decline in titer for at least 9.5 years after administration of Jeryl Lynn mumps virus vaccine (Mumpsvax). Antibodies were retained without important decline in children and adults for at least 7.5 and 7 years, respectively, after administration of HPV-77 duck-modified rubella vaccine (Meruvax). The patterns of antibody persistence 7.5 years after administration of combined measles-mumps-rubella (M-M-R) and mumps-rubella (Biavax) vaccines, 6 years after administration of measles-rubella vaccine (M-R-VAX), and 4 years after administration of measles-mumps vaccine (M-M-VAX) were the same as for the monovalent vaccines, indicating no alteration in the retention of immunity. Subclinical reinfection evidenced by increase in homologous antibody titer was observed to follow vaccination the same as occurs after natural infection.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 263873

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  10 in total

1.  Immunity to measles in the Croatian population.

Authors:  Berislav Borcić; Renata Mazuran; Bernard Kaić
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

Review 2.  Vaccines against human diarrheal pathogens: current status and perspectives.

Authors:  Nathalie Böhles; Nathalie Böhles; Kim Busch; Kim Busch; Michael Hensel; Michael Hensel
Journal:  Hum Vaccin Immunother       Date:  2014-05-26       Impact factor: 3.452

Review 3.  Mumps and varicella vaccines.

Authors:  J A Dudgeon
Journal:  Arch Dis Child       Date:  1980-01       Impact factor: 3.791

4.  Prevention of mumps.

Authors: 
Journal:  Br Med J       Date:  1980-11-08

5.  Rubella antibody titres and immunization status in a family practice.

Authors:  D A Mills; K R Parker; C E Evans
Journal:  Can Med Assoc J       Date:  1980-03-08       Impact factor: 8.262

6.  Mumps prophylaxis in the light of a new test for antibody.

Authors:  P P Mortimer
Journal:  Br Med J       Date:  1978-12-02

7.  Immune responses to mumps vaccine in adults who were vaccinated in childhood.

Authors:  Rima Hanna-Wakim; Linda L Yasukawa; Phillip Sung; Ann M Arvin; Hayley A Gans
Journal:  J Infect Dis       Date:  2008-06-15       Impact factor: 5.226

8.  Chapter 8 Paramyxoviruses.

Authors: 
Journal:  Perspect Med Virol       Date:  2008-05-29

9.  An Ad/MVA vectored Theileria parva antigen induces schizont-specific CD8+ central memory T cells and confers partial protection against a lethal challenge.

Authors:  Nicholas Svitek; Rosemary Saya; Elias Awino; Stephen Munyao; Robert Muriuki; Thomas Njoroge; Roger Pellé; Nicholas Ndiwa; Jane Poole; Sarah Gilbert; Vishvanath Nene; Lucilla Steinaa
Journal:  NPJ Vaccines       Date:  2018-09-11       Impact factor: 7.344

Review 10.  A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.

Authors:  David B Huang; Jashin J Wu; Stephen K Tyring
Journal:  J Infect       Date:  2004-10       Impact factor: 6.072

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.